Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic warning letter

This article was originally published in The Gray Sheet

Executive Summary

Firm's Synchromed II and MiniMed Paradigm insulin pumps are subject to a June 1 FDA warning letter. During a Nov. 12-Dec. 15, 2008, inspection of Medtronic's Puerto Rico manufacturing facility, FDA identified quality system violations related to manufacture of the Synchromed devices and medical device reporting violations related to the Paradigm pumps. For example, Synchromed pumps were distributed and implanted in patients without being filled with a necessary propellant, but the firm took nearly two years to conduct a recall. In addition, Medtronic failed to report device-related serious injuries to FDA in a timely manner, the agency charges

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel